First-of-Its-Kind Drug Shows Early Promise Against Prostate Cancer
Key Points:
- Researchers tested an experimental oral drug, bavdegalutamide (ARV-110), that degrades testosterone receptors to treat advanced prostate cancer resistant to conventional hormone therapies.
- In a combined phase I/II trial involving patients with metastatic castration-resistant prostate cancer, nearly 60% of those with T878/H875 gene mutations showed significant drops in prostate-specific antigen (PSA) levels, indicating a positive response.
- Patients with these mutations experienced a median progression time of 11 months before cancer worsened, compared to 4-5 months for others, suggesting the drug's potential effectiveness in this subset.
- Despite promising results, many participants reported side effects such as nausea, fatigue, vomiting, and diarrhea, prompting the developer Arvinas to focus on a related drug, ARV-766 (luxdegalutamide), which may have fewer adverse effects.
- The new drug represents a novel approach by accelerating degradation of androgen receptors, potentially overcoming resistance seen with existing therapies, but further studies are needed to confirm long-term benefits and safety.